• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals Inc (NQ: DAWN )

14.72 +0.25 (+1.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Day One Biopharmaceuticals Inc

< Previous 1 2 3 4 5 Next >
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
October 31, 2024
Via Benzinga
Day One Reports Third Quarter 2024 Financial Results and Corporate Progress
October 30, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024
October 16, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Analyst Ratings for Day One Biopharmaceutical
November 07, 2023
Via Benzinga
The Latest Analyst Ratings for Day One Biopharmaceutical
September 12, 2023
Via Benzinga
Bank of America Says Buy These 3 Stocks for a Double-Digit Rally
August 14, 2024
Despite fears of a recession roiling the markets, analysts say these are the best stocks to buy with an average upside potential of 72%. 
Via InvestorPlace
Topics Economy
Exposures Economy
Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
August 01, 2024
Via Benzinga
DAWN Stock Earnings: Day One Biopharmaceutical Beats EPS, Beats Revenue for Q2 2024
July 30, 2024
DAWN stock results show that Day One Biopharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Day One Reports Second Quarter 2024 Financial Results and Corporate Progress
July 30, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Oversubscribed $175.0 Million Private Placement
July 30, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
July 25, 2024
Via Benzinga
Week In Review: FutureGen Sells mAb For IBD To AbbVie In $1.7 Billion Deal
June 22, 2024
FutureGen Biopharm out-licensed global rights for its next-gen TL1A antibody to AbbVie in a $1.7 billion agreement. Also, MabCare Therapeutics out-licensed global rights for its ADC targeting... 
Via Talk Markets
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
June 18, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Sale of Priority Review Voucher for $108 Million
May 30, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
DAWN Stock Earnings: Day One Biopharmaceutical Misses EPS for Q1 2024
May 06, 2024
DAWN stock results show that Day One Biopharmaceutical missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
May 06, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
April 23, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
February 26, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Two New Appointments to Board of Directors
January 17, 2024
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
November 17, 2023
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual Meeting 
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
November 06, 2023
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Dow Up Over 340 Points As Stocks Snap Back
October 30, 2023
The Dow Jones Industrial Average is building on this morning's gains, up 343 points at last look, while the S&P 500 and Nasdaq Composite sit firmly in the black as well. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 30, 2023
Priority review granted with PDUFA target action date of April 30, 2024 
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 26, 2023
Via Benzinga
$15M Bet On Day One Biopharmaceuticals? Check Out These 3 Stocks Insiders Are Buying
October 23, 2023
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
September 11, 2023
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
August 16, 2023
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap